

PathWest Board Communiqué

This communiqué highlights key discussions and considerations from the September 2021 Board meeting.

Member attendance:

Prof. Christobel Saunders (Chair)	Ms. Angie Paskevicius
Dr. Sue van Leeuwen	Prof. Gelareh Farshid – <i>via VC</i>
Mr. Kevin Taylor	Dr. Kim Hames
Ms. Michele Dolin	Ms. Samantha Elder
Mr. Robert McPhee – <i>via VC</i>	

In attendance

Mr. Joe Boyle (Chief Executive)	Mr. Adrian Bautista
Ms. Analiese Sidhu	Prof. Miles Beaman
Mr. David Miotti	Ms. Nicola Chisholm

September 2021 Board Meeting

The September Board meeting was held at Fiona Stanley Hospital on Thursday, 2 September 2021.

The Board was pleased to welcome Department of Health Director General, Dr. Russell-Weisz to the Board meeting. Dr Russell-Weisz provided the PathWest Board and Executive with an update on the current overall status of Health in Western Australia, any implications for PathWest, and how we as a health service provider can support the wider health system. The Board and Executive took the opportunity to discuss a number of matters specific to PathWest, including:

- PathWest Infrastructure
- Your Voice in Health survey results
- Pricing and Costing project
- Governance Review
- CE and Board Chair appointment

The Board and Executive extend their thanks to Dr Russell-Weisz for making the time to attend our September Board meeting and share his insight on WA health issues.

Key matters for decision / discussion

- Draft PathWest Strategic Plan 2021-25.
The Board reviewed the draft Strategic Plan and noted the next steps for the Plan which include a detailed governance and reporting model to be finalised to oversee development of the operational plan, allocation of actions and monitoring of progress against the Plan. The Board will be providing feedback on the Plan through to the Office of the Chief Executive over the coming weeks.
- Single Discipline Structure.
The Board discussed the Single Discipline Structure proposal paper and agreed to defer any further discussions on progressing the proposal until the appointment of the new PathWest Chief Executive. It is foreseen that discussion on this matter will recommence in 2022.
- FY2020-21 Annual Financial Statements and Key Performance Indicators (KPI's) and Management Representation Letter.
Late advice (following the OAG Exit Meeting) was received by PathWest from the OAG regarding IT controls audit had been initiated late in the process. Given this, the PathWest Board decided to defer its decision on the FY2020-21 Annual Financial Statements and Key Performance Indicators (KPI's) and Management Representation Letter until further information has been provided.

Key matters for discussion:

- Finance and Business Report – July
- Budget (2021/22 update)
- Chief Executive Report
- PathWest Board and Committee evaluation

**Committee updates:**Finance Committee - 23 August 2021


- An overview was provided of the Procurement and Contract Management five-year forward procurement plan for active contracts, which does not include any out of contract spend (which is roughly 50%) and those classified as new procurement initiatives. The Committee raised an action for the November meeting requesting a 12-month view of all procurement activities with key milestones to assist with oversight for key decisions for the Committee.
- An update was provided on the Pricing and Costing project, with control of this project now transferred to the CFO, Adrian Bautista. Two years of activity data (FY2018/19 and FY2019/20) has been used in the Costing Model however there are still a number of key data inputs and assumptions which need to be verified and improved (i.e., Number of Tests Performed, Test Definitions, Test Allocations into Workstations, and FTE allocations). The next step is for each of the disciplines to be engaged to ensure consistent data and messaging. At this stage of the project, it is not intended for Forensic Biology to move to a fee for service model due to the block funded nature of the discipline. This, however, will be reviewed as part of the next phase.
- The process of the Medical Equipment Replacement Plan (MERP) was outlined to members, noting there is a constant government assessment of money available, with each HSP to put in a bid for a share of the money available.
- The July Finance and Business Report was reviewed in detail with it being noted the Net Cost of Service (NCOS) is favourable to budget.
- The Finance Committee reviewed the Terms of Reference; however, further discussions and endorsement was held over to the next meeting in November for members to further review the responsibilities of the Committee.
- The 2022 Finance Committee meeting calendar has been confirmed out of session.

Risk and Audit Committee | OAG Exit Meeting – 23 August 2021

- The OAG provided an exit briefing on matters arising from the external audit including an update on the proposed audit opinion in relation to:
 - Financial Statements
 - Controls and Legal Compliance
 - Performance Indicators
 - Actions for next year's audit
- The Risk and Audit Committee endorsed the Management Representation letter and the Financial Statements and KPIs for the 2020/21 and recommended the documents be tabled at Board for approval.

Next Meeting

The next scheduled Board meeting will be held at QEII Medical Campus on Thursday, 7 October 2021.


Professor Christobel Saunders
Chair, PathWest Board
9 September 2021



Christobel Saunders



Angie Paskevicius



Sue van Leeuwen



Kevin Taylor



Michele Dolin



Rob McPhee



Samantha Elder



Kim Hames



Gelareh Farshid